EA201990196A1 - Pyridopyrimidinone Inhibitors CDK2 / 4/6 - Google Patents

Pyridopyrimidinone Inhibitors CDK2 / 4/6

Info

Publication number
EA201990196A1
EA201990196A1 EA201990196A EA201990196A EA201990196A1 EA 201990196 A1 EA201990196 A1 EA 201990196A1 EA 201990196 A EA201990196 A EA 201990196A EA 201990196 A EA201990196 A EA 201990196A EA 201990196 A1 EA201990196 A1 EA 201990196A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cdk2
compounds
salts
pyridopyrimidinone
inhibitors
Prior art date
Application number
EA201990196A
Other languages
Russian (ru)
Other versions
EA036060B1 (en
Inventor
Дуглас Карл Бехенна
Пин Чэнь
Кевин Дэниэл Фриман-Кук
Роберт Луис Хоффман
Мехран Джалаи
Асако Нагата
Саджив Кришнан Наир
Саша Нинкович
Марта Алисия Орнелас
Синтия Луиз Палмер
Юджин Юаньцзинь Жуй
Original Assignee
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Инк. filed Critical Пфайзер Инк.
Priority claimed from PCT/IB2017/054655 external-priority patent/WO2018033815A1/en
Publication of EA201990196A1 publication Critical patent/EA201990196A1/en
Publication of EA036060B1 publication Critical patent/EA036060B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Данное изобретение относится к соединениям общей формулы (I) и их фармацевтически приемлемым солям, где R, R, R, R, R, R, R, R, R, R, R, R, p, q и r такие, как определено в данном документе, к фармацевтическим композициям, содержащим такие соединения и соли, и к способам использования таких соединений, солей и композиций для лечения аномального роста клеток, в том числе рака.This invention relates to compounds of the general formula (I) and their pharmaceutically acceptable salts, where R, R, R, R, R, R, R, R, R, R, R, R, p, q and r are as defined in this document, to pharmaceutical compositions containing such compounds and salts, and to methods of using such compounds, salts and compositions for treating abnormal cell growth, including cancer.

EA201990196A 2017-07-17 2017-07-31 Pyridopyrimdinone cdk2/4/6 inhibitors EA036060B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762533347P 2017-07-17 2017-07-17
PCT/IB2017/054655 WO2018033815A1 (en) 2016-08-15 2017-07-31 Pyridopyrimdinone cdk2/4/6 inhibitors

Publications (2)

Publication Number Publication Date
EA201990196A1 true EA201990196A1 (en) 2019-07-31
EA036060B1 EA036060B1 (en) 2020-09-21

Family

ID=67399623

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990196A EA036060B1 (en) 2017-07-17 2017-07-31 Pyridopyrimdinone cdk2/4/6 inhibitors

Country Status (1)

Country Link
EA (1) EA036060B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4046999A4 (en) * 2019-10-17 2023-11-22 Cisen Pharmaceutical Co., Ltd. Aminopyrimidine compound as cdk2/4/6 triple inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6498163B1 (en) * 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
CN1433417A (en) * 2000-01-27 2003-07-30 沃尼尔·朗伯公司 Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
PL218692B1 (en) * 2002-01-22 2015-01-30 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES
US20060142312A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
CN102015704A (en) * 2008-04-29 2011-04-13 霍夫曼-拉罗奇有限公司 Pyrimidinyl pyridone inhibitors of JNK

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4046999A4 (en) * 2019-10-17 2023-11-22 Cisen Pharmaceutical Co., Ltd. Aminopyrimidine compound as cdk2/4/6 triple inhibitor

Also Published As

Publication number Publication date
EA036060B1 (en) 2020-09-21

Similar Documents

Publication Publication Date Title
PH12019500329A1 (en) Pyridopyrimdinone cdk2/4/6 inhibitors
EA201790492A1 (en) CONNECTIONS THAT INHIBIT McL-1 PROTEIN
EA201692114A1 (en) SUBSTITUTED DIHYDRO-ISOHINOLINE NON COMPOUNDS
EA201891191A1 (en) 2-SUBSTITUTED HINAZOLIN COMPOUNDS CONTAINING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF THEIR APPLICATION
EA201891494A1 (en) HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
EA201790078A1 (en) MNK INHIBITORS AND RELATED METHODS
EA201790595A1 (en) Pyrimidinones as inhibitors of the XIA factor
EA201891063A1 (en) DERIVATIVES OF DIHYDROIMIDAZOPIRAZINONE APPLICABLE IN THE TREATMENT OF CANCER
EA201692079A1 (en) INHIBITORS OF LYSINE-SPECIFIC DEMETILASE-1
EA201590879A1 (en) ARYL-CONDENSED AND HETEROARYL-CONDENSED LACTAMS
EA201790779A1 (en) SUBSTITUTED AMINOPURIN COMPOUNDS, THEIR COMPOSITIONS AND METHODS OF TREATMENT USING SUCH CONNECTIONS
EA201792425A1 (en) TRICYCLIC COMPOUNDS AND THEIR APPLICATION AS PHOSPHODYSTERASE INHIBITORS
EA201692260A1 (en) 1,3,4-TIADIAZOLE COMPOUNDS AND THEIR APPLICATION IN CANCER TREATMENT
EA201691962A1 (en) AMIDOSED NITROGEN COMPOUNDS AS TNKS1 AND / OR TNKS2 INHIBITORS
EA201790830A1 (en) ALDOSTERONSYNTASE INHIBITORS
EA201790253A1 (en) ALDOSTERONSYNTASE INHIBITORS
PH12016501997B1 (en) Cycloalkyl-linked diheterocycle derivatives
EA201891319A1 (en) COMPOUNDS OF ALKYDYDYDROCHINOLINSULPHONAMIDE
EA201990196A1 (en) Pyridopyrimidinone Inhibitors CDK2 / 4/6
EA201792676A1 (en) JAK1 INHIBITORS
EA202092239A1 (en) MCL-1 INHIBITORS
EA201992303A1 (en) COMPOUNDS THAT INHIBIT Mcl-1 PROTEIN
EA201991524A1 (en) BENZOXAZOLE DERIVATIVES AS IMMUNOMODULATORS
EA201891621A1 (en) INHIBITION OF ATAXIA-TELEEGIEGASTASIA AND RAD3-RELATED PROTEIN (ATR)
EA201990686A1 (en) NAPHTHIRIDINE COMPOUNDS AS JAK KINASE INHIBITORS